Immune Restoration Protocol
Overview
The Immune Restoration Protocol targets chronic immune dysfunction including post-viral syndromes (long COVID, EBV reactivation), recurrent infections, immune senescence in aging, and chronic fatigue with immunological components. Thymosin Alpha-1 is the cornerstone — the most clinically validated immunomodulatory peptide globally, with clinical use in over 35 countries. LL-37 provides antimicrobial defense and immune bridge function while KPV controls inflammatory overflow. Expected outcomes include improved NK cell activity, T-cell competence, reduced viral reactivation, and improvement in fatigue and immune-related symptoms.
Components
| Peptide | Dose | Frequency | Duration |
|---|---|---|---|
| Thymosin Alpha-1 | 1.6 mg | 2x/week SubQ | 8-12 weeks |
| LL-37 | 100-200 mcg | 2-3x/week SubQ | 4-8 weeks |
| KPV | 200-500 mcg | Daily oral (or SubQ) | 4-8 weeks |
Administration
- Thymosin Alpha-1: SubQ injection; any convenient site; reconstitute in sterile/bacteriostatic water; stable 30 days refrigerated; the 1.6mg dose mirrors the clinically studied dose from hepatitis B/C and cancer adjunct trials
- LL-37: SubQ injection; may cause transient injection site warmth (immune activation response — expected); start at lower end of dose range
- KPV: Oral capsule or dissolved in water (stable for mucosal administration); empty stomach enhances absorption; can also be taken SubQ for systemic effect
- Schedule: Thymosin Alpha-1 Mon/Thu is a common pairing for the 2x/week schedule
Cycling
- Acute phase (active infection, post-viral): 4-8 weeks at stated doses
- Maintenance / immune optimization: 1.6mg Thymosin Alpha-1 once weekly ongoing, or pulsed 3-month courses
- LL-37 and KPV: Cycle with 4 weeks on / 2-4 weeks off
- Re-evaluate immune function labs at end of each cycle
Expected Timeline
- Week 1-2: Subjective energy improvement; reduced frequency of acute illness
- Week 3-4: NK cell activity increases measurable in labs; fatigue improving
- Week 6-8: Significant improvement in post-viral symptoms and chronic infection burden
- Week 10-12: Immune competence approaching normal; maintenance phase begins
Monitoring
- Immune panel at baseline and 8 weeks: NK cell count and activity, CD4/CD8 ratio, lymphocyte subsets
- Inflammatory markers: CRP, ESR, IL-6
- Track symptom burden (fatigue, infection frequency, lymph node status)
- Autoimmune markers if autoimmune component suspected (ANA, anti-dsDNA)
Contraindications
- Organ transplant recipients on immunosuppressants (Thymosin Alpha-1 may counteract immunosuppression)
- Active autoimmune flare with evidence of overactive immunity (caution — consult specialist)
- Thymic malignancies
- Pregnancy or breastfeeding
Sources
#protocol #immune #ThymosinAlpha1 #LL37 #KPV #postviral #longcovid #immunerestoration